scholarly journals Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

2012 ◽  
pp. 159 ◽  
Author(s):  
Albert Tuca ◽  
Ernest Guell ◽  
Emilio Martinez-Losada ◽  
Nuria Codorniu
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Spontaneous Resolution ◽  
Malignant Bowel Obstruction ◽  
Advanced Cancer Patients ◽  
Factors Influencing

Can malignant bowel obstruction in advanced cancer patients be treated at home?

2010 ◽  
Vol 19 (3) ◽  
pp. 431-433 ◽  
Author(s):  
Giampiero Porzio ◽  
Federica Aielli ◽  
Lucilla Verna ◽  
Brigida Galletti ◽  
Ghazaleh Shoja e Razavi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Malignant Bowel Obstruction ◽  
Advanced Cancer Patients ◽  
At Home

Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction

2020 ◽  
Vol 23 (7) ◽  
pp. 880-881
Author(s):  
Keisuke Kaneishi ◽  
Kengo Imai ◽  
Kazunori Nishimura ◽  
Norio Sakurai ◽  
Hiroyuki Kohara ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Nausea And Vomiting ◽  
Malignant Bowel Obstruction ◽  
Advanced Cancer Patients

Use of parenteral nutrition in patients with advanced cancer

2008 ◽  
Vol 33 (1) ◽  
pp. 102-106 ◽  
Author(s):  
Isaac Soo ◽  
Leah Gramlich
Keyword(s):  
Parenteral Nutrition ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Intestinal Failure ◽  
Advanced Cancer Patients ◽  
End Stage ◽  
Northern Alberta

The purpose of this study is to describe patient-related variables in a cohort of advanced cancer patients (ACPs) enrolled in a home parenteral nutrition (HPN) program. This study reviewed the cohort of ACPs enrolled in the Northern Alberta Home Total Parenteral Nutrition Program (NAHTPNP). Thirty-eight ACPs received HPN during the study period, 24% of all patients admitted for PN. Of these, 27 (71%) were female. Mean age was 48.76 y (SD 13.8 y). Bowel obstruction was the most common indication for initiating HPN (84%, 32) and ovarian cancer was the most common malignancy (34%, 13). Patients who began HPN with a Karnofsky performance status (KPS) of greater than 50 (median of 70) were found to have a longer duration of life (median: 6 months) compared with patients who began HPN with a KPS of 50 or below (median = 50; median 3 months; p = 0.01; two-tailed). There was no difference in survival between malignancy type (p = NS). Advanced cancer is the fastest growing indication for enrollment in the HPN program. ACP demonstrated a 3% average annual increase proportionate to all indications for HPN starts, accounting for 7%–48% of HPN starts from 1999–2006. HPN is an increasingly used therapy for patients with advanced cancer, most commonly for intestinal failure in the setting of bowel obstruction. Initiation of HPN at a higher KPS was associated with a longer duration of life. Further studies are needed to validate the use of TPN in end-stage cancer patients.

Factors influencing advanced cancer patients’ preferences for quality or length of life.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 9576-9576
Author(s):  
Eva C. Winkler ◽  
Halina Sklenarova ◽  
Mechthild Hartmann ◽  
Pia Heussner ◽  
Matthias Villalobos ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Advanced Cancer Patients ◽  
Factors Influencing ◽  
Length Of Life

scholarly journals Episodic Breathlessness with and without Background Dyspnea in Advanced Cancer Patients Admitted to an Acute Supportive Care Unit

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2102
Author(s):  
Sebastiano Mercadante ◽  
Claudio Adile ◽  
Patrizia Ferrera ◽  
Giuseppe Bonanno ◽  
Vincenzo Restivo ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Advanced Cancer Patients ◽  
Clinical Appearance ◽  
Factors Influencing ◽  
Numerical Scale ◽  
The Mean

Aim: To characterize episodic breathlessness (EB) in patients with advanced cancer, and to determine factors influencing its clinical appearance. Methods: A consecutive sample of advanced cancer patients admitted to an acute palliative care unit was surveyed. Continuous dyspnea and EB were measured by a numerical scale. The use of drugs used for continuous dyspnea and EB was recorded. Patients were asked about the characteristics of EB (frequency, intensity, duration and triggers). The Multidimensional dyspnea profile (MDP), the Brief dyspnea inventory (BDI), the Athens sleep scale (AIS) and the Hospital Anxiety and Depression Scale (HADS) were also administered. Results: From 439 advanced cancer patients surveyed, 34 and 27 patients had EB, without and with background dyspnea, respectively. The mean intensity and the number of episodes were higher in patients with background dyspnea (p < 0.0005 and p = 0.05, respectively). No differences in duration were observed. Most episodes lasted <10 min. A recognizable cause triggering EB was often found. The presence of both background dyspnea and EB was associated with higher values of MDP and BDI. EB was independently associated with frequency and intensity of background dyspnea (OR = 20.9, 95% CI (Confidence interval) 9.1–48.0; p < 0.0005 and OR = 1.97, 95% CI 1.09–3.58; p = 0.025, respectively) and a lower Karnofsky level (OR = 0.96, 95%CI 0.92–0.98, p = 0.05). Discussion: EB may occur in patients with and without continuous dyspnea, and is often induced by physical and psychological factors. EB intensity is higher in patients with continuous dyspnea. The duration was often so short that the use of drugs, as needed, may be too late, unless administered pre-emptively when the trigger was predictable.

Sign in / Sign up

Export Citation Format

Share Document